Exact Sciences Corp (EXAS) FinancialsEXASFinancialExact Sciences Corp

Exact Sciences Corp (EXAS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial, accounting for 47.6% of total sales, equivalent to $405.24M. Other significant revenue streams include Medicare Parts B & C and Other. Understanding this composition is critical for investors evaluating how EXAS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Exact Sciences Corp maintains a gross margin of 70.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -9.36%, while the net margin is -9.79%. These profitability ratios, combined with a Return on Equity (ROE) of -8.66%, provide a clear picture of how effectively EXAS converts its operational activities into shareholder value.

In the context of the broader market, EXAS competes directly with industry leaders such as ILMN and STE. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, EXAS's gross margin of 70.11% stands against ILMN's 66.44% and STE's 45.84%. Such benchmarking helps identify whether Exact Sciences Corp is trading at a premium or discount relative to its financial performance.

In Q4 2025, revenue increased by 23.12% YoY to $878.38 million, but net income dropped by 90.06% YoY to -$85.96 million. EPS also declined by 90.36% YoY to -0.45, despite an improvement in gross margin to 70.11%, up 16.52% YoY.